Marina Biotech said the Intellectual Property Office of New Zealand (IPONZ) has issued a notice of acceptance for patent application 563845, titled ‘RNAi Therapeutics for Respiratory Virus Infection.’
Allowed claims cover siRNA directed against the PB2 and may be used to treat or prevent influenza.
Further, the Mexican Institute of Industrial Property issued patent application MX/a/2007/003667, titled ‘Methods of Treating an Inflammatory Disease by Double-Stranded Ribonucleic Acid.’
The allowed claims cover siRNA directed against the tumor necrosis factor (TNF) gene and may be used for treating multiple inflammatory diseases.
Marina Biotech president and CEO Michael French said the advancement of safe and effective RNAi-based delivery systems remains a key goal for Marina Biotech in their efforts to discover and develop novel RNAi-based therapeutics.
"In connection with this recent European allowance, we are amassing a significant intellectual property estate covering a peptide-based delivery system including targeting peptides derived from our patented phage display peptide library, nucleic acid condensing peptides, and peptide-nucleic acid conjugates," French said.